drugset

drugset / Trial / NCT01405118

Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

NCT01405118 ↗

Phase 1 Completed 24 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study will evaluate the potential effect of CP 690,550 on the pharmacokinetics of metformin, a probe drug for organic cationic transport.

Timeline

Start: 2011-06
Primary completion: 2011-07
Completion: 2011-07

Publications

Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. Clin Pharmacol Drug Dev. 2014 Nov;3(6):499-507. doi: 10.1002/cpdd.120. Epub 2014 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	500 mg	Oral
Subject	Tofacitinib	Small molecule	30 mg	Oral

Indications